Tag: Pharmaceuticals
-
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo asked the court to permanently stop Lilly from running the “deceptive” ads and require the drugmaker to issue corrective advertising.
-
What to know about testosterone replacement therapy as the U.S. military plans to test troops
While some research has shown benefits for patients who qualify, questions remain about the therapy’s long-term risks and use among men without a medical need.
-
The market for psychedelic drugs to treat mental health conditions gets a big buy signal
Eli Lilly’s acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma’s embrace of a stigmatized class of medications for treating mental health.
-
Fat cat? Weight-loss drugs may be coming for your overweight pet
Startups are testing GLP-1 treatments for overweight cats while pet-food giants are leaning into longevity products as owners spend more on animal health.
-
UnitedHealth blows past estimates, hikes earnings outlook as it reins in costs
The healthcare giant is working to stabilize margins by shrinking membership, exiting unprofitable contracts and pouring $1.5 billion into AI.
-
Johnson & Johnson has a chance to show it’s more than just a rotation winner
The healthcare giant’s second-quarter earnings will shine the spotlight on its exciting new products and pipeline.
-
HSBC loses conviction in leading drugmaker, forecasts ‘tough path’ ahead
The bank’s analysts wrote in a note on Monday that they have downgraded the stock to ‘hold’, as the team “no longer finds the risk-reward balance attractive.”
-
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk’s obesity injection Wegovy and diabetes counterpart Ozempic.
-
AstraZeneca’s trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.
-
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Its latest fundraising round provides the French biotech with enough cash to finance operations through 2029.
Latest News
Stay Connected
Categories
BBC News CNA CNBC CNN International Deutsche Welle (DW) Euronews France 24 General Global & European Specialized & Regional
Tags
amp Artificial intelligence Asia Breaking News: Business Breaking News: Markets Breaking News: Politics Breaking News: Technology Business business news cent china cup Donald J. Trump Donald Trump economy European Union fast football France germany india Investment strategy iran Iran war markets People per politics return russia S&P 500 Index said Singapore spain Sport Stock markets technology trump ukraine United States US-Israel attack on Iran 2026 video War in Ukraine World World Cup 2026
About the Author
AF themes
Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.
Search the Archives
Access over the years of investigative journalism and breaking reports
You May Have Missed
